At 4.2% CAGR, the Middle East & Africa ELISA Diagnostics Tests Market is Projected to be worth US$ 94.26 million by 2030, says Business Market Insights
According to Business Market Insights research, the Middle East & Africa ELISA diagnostics tests market was valued at US$ 67.74 million in 2022 and is expected to reach US$ 94.26 million by 2030, registering a CAGR of 4.2% from 2022 to 2030. Rising infectious diseases among animals and innovative product launches are among the critical factors attributed to the Middle East & Africa ELISA diagnostics tests market expansion.
The World Organization for Animal Health published a report revealing that 60% of human infections comprise animal-related diseases. It also mentioned that 75% of emerging animal diseases can be transmitted to humans, and there are five emerging diseases among animals annually. Every year, about 55,000 healthcare claims are associated with rabies infection worldwide, comprising mainly children due to infected dog bites as per the WHO report. Further, the Health for Animals report reveals that six animal-related diseases (Hantavirus, Lymphocytic, Choriomeningitis virus (LCMV), plague, salmonella, rat bite fever, and tularemia) caused economic losses worth US$ 80 billion within 12 years. Among six, just one animal-related disease, "Foot and Mouth," costs farmers up to US$ 21 billion globally every year.
The persistent lymphocytosis (PL) present among cows can infect their calves during pregnancy. Cows can suffer from serious milk production declines and may infect other surrounding animals. In this scenario, Enzyme-Linked Immunosorbent Assay (ELISA) test is best suited to test infected cows positive for PL disease as it reveals proper lymphocyte count clinical results on testing. Further, the test is reported by veterinarian to be 95% sensitive for animals infected with 55 days of infection. Therefore, ELISA test is commonly recommended by veterinarian for animals aged 8 months and above. Thus, rising incidence of animal-associated diseases propels the demand for ELISA tests.
On the contrary, incidents of product recalls hamper the growth of Middle East & Africa ELISA diagnostics tests market.
Based on adoption, the Middle East & Africa ELISA diagnostics tests market is bifurcated into human and veterinary. The human segment held 65.5% market share in 2022, amassing US$ 44.38 million. It is projected to garner US$ 64.28 million by 2030 to expand at 4.7% CAGR during 2022-2030.
In terms of test type, the Middle East & Africa ELISA diagnostics tests market is categorized into sandwich ELISA, indirect ELISA, competitive ELISA, and multiple & portable ELISA. The indirect ELISA segment held 35.4% share of Middle East & Africa ELISA diagnostics tests market in 2022, amassing US$ 23.96 million. It is projected to garner US$ 36.48 million by 2030 to expand at 5.4% CAGR during 2022-2030.
Based on application, the Middle East & Africa ELISA diagnostics tests market is categorized into autoimmune diseases, infectious diseases, cancer diagnosis, protein quantification, and others. The infectious diseases segment held 41.2% share of Middle East & Africa ELISA diagnostics tests market in 2022, amassing US$ 27.90 million. It is projected to garner US$ 41.94 million by 2030 to expand at 5.2% CAGR during 2022-2030.
By end user, the Middle East & Africa ELISA diagnostics tests market is categorized into hospitals & diagnostic centers, pharmaceutical & biotechnology companies, veterinary hospitals & diagnostic laboratories, and others. The hospitals & diagnostic centers segment held 40.3% share of Middle East & Africa ELISA diagnostics tests market in 2022, amassing US$ 27.29 million. It is projected to garner US$ 40.69 million by 2030 to expand at 5.1% CAGR during 2022-2030.
Based on country, the Middle East & Africa ELISA diagnostics tests market has been categorized into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 31.5% share of Middle East & Africa ELISA diagnostics tests market in 2022. It was assessed at US$ 21.31 million in 2022 and is likely to hit US$ 32.19 million by 2030, exhibiting a CAGR of 5.3% during 2022-2030.
Key players operating in the Middle East & Africa ELISA diagnostics tests market are Bio-Rad Laboratories Inc., Idexx Laboratories Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corp., DiaSorin SpA, and Elabscience Biotechnology Inc., among others.
In April 2021, Roche launches Elecsys Anti-p53 immunoassay to aid diagnosis of various cancer types.
In June 2022, IDEXX Empowers Veterinarians with New Testing Insights that Support Earlier Diagnosis and Intervention for Preventive Care and Critical Cases.
Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com
